Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04927143 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives

StatusCompleted
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment target: 600 to 206
    • Trial completed
  2. Minor Trial status: Recruiting to Completed Show 5 more changesShow less
    • Primary and study completion dates changed from estimate of Sep 2026 to Sep 25, 2026
    • Eligibility criteria expanded, about 11 words
    • Study description revised
    • Site details revised at 2 of 2 sites
    • Publications: details revised at 22 of 24 entries
  3. Minor Re-verified, no change to tracked fieldsv17
  4. Notable Primary completion date: Sep 2025 to Sep 2026
    • Study completion date: Dec 2025 to Sep 2026
    v16
  5. Minor Re-verified, no change to tracked fieldsv15
Show 13 earlier versionsHide 13 earlier versions
  1. Notable Phase: Phase 2 to Not applicablev14 Show 7 more changesShow less
    • Lead sponsor: University of California Santa Cruz to Wake Forest University Health Sciences
    • Primary endpoints: 1 to 2
    • Interventions: App-Based Contingency Management (Device), Sham Control (Behavioral) to App-Based Contingency Management (Behavioral), Sham Control (Behavioral)
    • Eligibility criteria revised
    • Secondary endpoints expanded, about 21 words
    • Collaborators: 2 to 3
    • Study title expanded, about 3 words
  2. Notable Lead sponsor: Wake Forest University Health Sciences to University of California Santa Cruzv13 Show 4 more changesShow less
    • Primary completion date: Sep 2024 to Sep 2025
    • Study completion date: Dec 2024 to Dec 2025
    • Site contacts updated at 1 of 2 sites
    • Collaborators: 3 to 2
  3. Minor Collaborators reorderedv12
  4. Notable Primary completion date: Jan 2024 to Sep 2024
    • Study completion date: Jun 2024 to Dec 2024
    v11
  5. Notable Primary completion date: Jun 2023 to Jan 2024v10
  6. Minor Re-verified, no change to tracked fieldsv9
  7. Minor Study sites revised (2)v8
  8. Notable Phase: Phase 3 to Phase 2
    • Interventions: App-Based Contingency Management (Behavioral), Sham Control (Behavioral) to App-Based Contingency Management (Device), Sham Control (Behavioral)
    v7
  9. Minor Re-verified, no change to tracked fieldsv6
  10. Minor Study description shortened, about 191 words
    • Study arms: 5 to 7
    • Eligibility criteria expanded, about 5 words
    v5
  11. Notable Primary endpoints: 3 to 1
    • Secondary endpoints shortened, about 9 words
    v4
  12. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date: Aug 2021 to Sep 15, 2021
    v3
  13. Minor Study description revisedv2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Combatting the rise of the opioid epidemic is a central challenge of U.S. health care policy. A promising approach for improving welfare and decreasing medical costs of people with substance abuse disorders is offering incentive payments for healthy behaviors. This approach, broadly known as "contingency management" in the medical literature, has repeatedly shown to be effective in treating substance abuse. However, the use of incentives by treatment facilities remains extremely low. Furthermore, it is not well understood how to design optimal incentives to treat opioid abuse. This project will conduct a randomized evaluation of two types of dynamically adjusting incentive schedules for people with opioid use disorders or cocaine use disorders: "escalating" schedules where incentive amounts increase with success to increase incentive power, and "de-escalating" schedules where incentive amounts decrease with success to improve incentive targeting. Both schemes are implemented with a novel "turnkey" mobile application, making them uniquely low-cost, low-hassle, and scalable. Effects will be measured on abstinence outcomes, including longest duration of abstinence and the percentage of negative drug tests. In combination with survey data, variation from the experiment will shed light on the barriers to abstinence more broadly and inform the understanding of optimal incentive design.
Trial Details
NCT Number NCT04927143
Lead Sponsor Wake Forest University Health Sciences
Collaborators: University of Chicago, Rogers Behavioral Health, University of California Santa Cruz
Conditions
(from sponsor)
Opioid-use Disorder, Cocaine Use Disorder, Opioid Use, Cocaine Use, Substance Use, Methamphetamine Abuse, Methamphetamine-dependence
Related terms Opioid-Related Disorders, Substance-Related Disorders
Enrollment 206 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov